Alice Di Rocco

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert et al. · The Lancet · 2019 · 253 citations · Full text

Medicine, Oncology, Cancer Immunology +10

Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi

Francesco Merli, Stefano Luminari, Alessandra Tucci et al. · Journal of Clinical Oncology · 2021 · 160 citations · Full text

Medicine, Geriatric Medicine, Oncology +15

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

Carlo Visco, Annalisa Chiappella, Luca Nassi et al. · The Lancet Haematology · 2016 · 138 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Simone Ferrero, Davide Rossi, Andrea Rinaldi et al. · Haematologica · 2019 · 135 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Michael Crump, Sirpa Leppä, Luis Fayad et al. · Journal of Clinical Oncology · 2016 · 126 citations

Medicine, Oncology, Pharmacotherapy +13